Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a ...

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

“More advanced disease requires more invasive treatments.” And those with high-risk non-muscle-invasive bladder cancer, are usually offered a transurethral resection of a bladder tumour ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...